MAPT and Alzheimer disease: In addition, treatment with protein-capped (PC) Fe3O4 and PC-cadmium NPs can act as potent tau aggregation inhibitors in AD cells, which may provide a novel strategy to design anti-tau aggregation drugs for AD patients (Sonawane et al., 2019).